Welcome to LookChem.com Sign In|Join Free
  • or
(2R,6R,11R)-3,6,11-Trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

67009-58-9

67009-58-9 Suppliers

This product is a nationally controlled contraband or patented product, and the Lookchem platform doesn't provide relevant sales information.

67009-58-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 67009-58-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,7,0,0 and 9 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 67009-58:
(7*6)+(6*7)+(5*0)+(4*0)+(3*9)+(2*5)+(1*8)=129
129 % 10 = 9
So 67009-58-9 is a valid CAS Registry Number.

67009-58-9Relevant academic research and scientific papers

Enantiopure n-acyldihydropyridones as synthetic intermediates: Asymmetric synthesis of benzomorphans

Comins, Daniel L.,Zhang, Yue-Mei,Joseph, Sajan P.

, p. 657 - 659 (2008/02/12)

(Matrix presented) Concise asymmetric syntheses of several benzomorphan derivatives have been accomplished using enantiopure 2,3-dihydro-4-pyridones as chiral building blocks.

Antipodal α-N-(methyl through decyl)-N-normetazocines (5,9α-dimethyl- 2'-hydroxy-6,7-benzomorphans): In vitro and in vivo properties

May,Aceto,Bowman,Bentley,Martin,Harris,Medzihradsky,Mattson,Jacobson

, p. 3408 - 3418 (2007/10/02)

The enantiomeric (-)- and (+)-N-(methyl through decyl) normetazocines (5,9α-dimethyl-2'-hydroxy-6,7-benzomorphans) were synthesized and their in vitro and in vivo activities determined. Increasingly bulky enantiomeric N- alkyl homologs were prepared until their interaction with the σ1 receptor decreased and their insolubility became a hindrance to their evaluation in vivo and/or in vitro. The (-)-methyl, -pentyl, -hexyl, and -heptyl homologs were essentially as potent as, or more potent than, morphine in the tail- flick, phenylquinone, and hot-plate assays for antinociceptive activity; the (-)-propyl homolog had narcotic antagonist activity between that of nalorphine and naloxone in the tail-flick vs morphine assay, and it also displayed antagonist properties in the single-dose suppression assay in the rhesus monkey. The antinociceptively potent (-)-heptyl homolog did not substitute for morphine in monkeys but did show morphine-like properties in a primary physical-dependence study in continuously infused rats. All five potent compounds showed high affinity for the μ opioid receptor from both rat and monkey preparations and the κ opioid receptor (0.05 μM), and all except the (-)-methyl homolog interacted reasonably well at the δ receptor (K(i) 0.1 μM). The (-)-propyl compound was equipotent (K(i) 1.5-2.0 nM) at μ and κ receptors. The pattern of interaction of the (-)-enantiomeric homologs with μ receptors from rat and monkey preparations was similar, but not identical. The enantioselectivity of the homologs for μ receptors was greater in the rat than in the monkey preparation for all but the N-H and butyl compounds, and the enantioselectivity of the lower homologs (methyl through butyl) for the μ (monkey) receptor was greater than for the κ or δ receptors. However, bulkier homologs (hexyl through decyl) displayed higher enantioselectivity at κ or δ receptors than at the μ (monkey) receptor. The (+)-butyl through (+)-octyl homologs were essentially equipotent with, or more potent than, (+)-pentazocine at the σ receptor. Only the (+)-H and (+)- methyl homologs had high affinity (0.05 μM) at PCP binding sites.